These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37022666)

  • 1. Efanesoctocog Alfa: First Approval.
    Keam SJ
    Drugs; 2023 May; 83(7):633-638. PubMed ID: 37022666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA
    Expert Rev Hematol; 2023; 16(8):567-573. PubMed ID: 37289594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.
    Dargaud Y; Leuci A; Ruiz AR; Lacroix-Desmazes S
    Haematologica; 2024 Aug; 109(8):2436-2444. PubMed ID: 38356459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
    N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L; Peyvandi F; Chan AKC; Königs C; Zulfikar B; Yuan H; Simpson M; Álvarez Román MT; Carcao M; Staber JM; Dunn AL; Chou SC; d'Oiron R; Albisetti M; Demissie M; Santagostino E; Yarramaneni A; Wong N; Abad-Franch L; Gunawardena S; Fijnvandraat K;
    N Engl J Med; 2024 Jul; 391(3):235-246. PubMed ID: 39018533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
    J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
    Ryu JH; Bauer KA; Schulman S
    J Thromb Haemost; 2023 Dec; 21(12):3508-3510. PubMed ID: 37734716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
    Lissitchkov T; Willemze A; Katragadda S; Rice K; Poloskey S; Benson C
    Blood Adv; 2022 Feb; 6(4):1089-1094. PubMed ID: 34794179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A.
    Yada K; Nogami K
    Expert Opin Drug Metab Toxicol; 2024 Oct; ():1-10. PubMed ID: 39323385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lonoctocog Alfa: A Review in Haemophilia A.
    Al-Salama ZT; Scott LJ
    Drugs; 2017 Oct; 77(15):1677-1686. PubMed ID: 28900904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
    Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
    Vollack-Hesse N; Oleshko O; Werwitzke S; Solecka-Witulska B; Kannicht C; Tiede A
    Blood; 2021 Feb; 137(8):1072-1081. PubMed ID: 32877516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
    Lissitchkov T; Willemze A; Jan C; Zilberstein M; Katragadda S
    Res Pract Thromb Haemost; 2023 May; 7(4):100176. PubMed ID: 37538505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.